Showing results (371-380 of 561) with videos related to

Sort By:
Pageof 57
The Lancet. Oncology|February 18, 2017
Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trialRobert Glynne-Jones, David Sebag-Montefiore, Helen M Meadows, et al.
British Journal of Haematology|July 5, 2020
FDG-PET/CT after two cycles of R-CHOP in DLBCL predicts complete remission but has limited value in identifying patients with poor outcome - final result of a UK National Cancer Research Institute prospective studyN George Mikhaeel, David Cunningham, Nicholas Counsell, et al.
Clinical Pharmacokinetics|September 6, 2015
Phase I Population Pharmacokinetic Assessment of the Oral Bromodomain Inhibitor OTX015 in Patients with Haematologic MalignanciesElodie Odore, François Lokiec, Esteban Cvitkovic, et al.
World Journal of Nuclear Medicine|July 22, 2022
The Diagnostic Accuracy of 18 F-FGD-PET/CT for Cancer of the Gallbladder: A Retrospective StudyStephanos Pericleous, Sophie L F Doran, Andrew Wotherspoon, et al.
International Journal of Radiation Oncology, Biology, Physics|June 3, 2015
Short- and Long-Term Quality of Life and Bowel Function in Patients With MRI-Defined, High-Risk, Locally Advanced Rectal Cancer Treated With an Intensified Neoadjuvant Strategy in the Randomized Phase 2 EXPERT-C TrialFrancesco Sclafani, Clare Peckitt, David Cunningham, et al.
Diseases of the Esophagus : Official Journal of the International Society for Diseases of the Esophagus|June 28, 2020
Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trialNaser Davarzani, Lindsay C Hewitt, Matthew D Hale, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancerIan Chau, Andrew R Norman, David Cunningham, et al.
JAMA Oncology|December 6, 2016
Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical TrialManish A Shah, Yung-Jue Bang, Florian Lordick, et al.
Pancreas|December 20, 2019
Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPOLI-1 TrialTeresa Macarulla Mercadé, Li-Tzong Chen, Chung-Pin Li, et al.
Health Technology Assessment (Winchester, England)|February 4, 2014
The clinical effectiveness and cost-effectiveness of ablative therapies in the management of liver metastases: systematic review and economic evaluationEmma Loveman, Jeremy Jones, Andrew J Clegg, et al.
Pageof 57